NKTR
|Nektar Therapeutics
NASDAQ
USD 0.75
-0.05|-5.89%
Current Price
USD 0.75
Change
USD -0.05 (-5.89%)
P/E Ratio
Dividend Yield
Market Cap
125.53M
Volume
2.44M
Open
USD 0.79
Previous Close
USD 0.80
52-Week High
USD 1.52
52-Week Low
USD 0.43
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Howard W. Robin
Employees:61
Headquarters:San Francisco, USA
Website:www.nektar.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions